1. Home
  2. PCRX vs ANAB Comparison

PCRX vs ANAB Comparison

Compare PCRX & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

SELL

Current Price

$36.48

Market Cap

1.5B

Sector

Health Care

ML Signal

SELL

Logo AnaptysBio Inc.

ANAB

AnaptysBio Inc.

SELL

Current Price

$45.77

Market Cap

1.4B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PCRX
ANAB
Founded
2006
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.4B
IPO Year
2010
2015

Fundamental Metrics

Financial Performance
Metric
PCRX
ANAB
Price
$36.48
$45.77
Analyst Decision
Hold
Strong Buy
Analyst Count
9
8
Target Price
$33.57
★ $87.25
AVG Volume (30 Days)
★ 958.5K
367.2K
Earning Date
11-09-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 107.44
91.02
EPS
★ 0.89
0.11
Revenue
★ $541,533,000.00
$234,603,000.00
Revenue This Year
$3.84
$28.82
Revenue Next Year
$4.73
$24.35
P/E Ratio
★ $40.96
$420.73
Revenue Growth
26.04
★ 157.01
52 Week Low
$18.80
$33.10
52 Week High
$36.67
$73.30

Technical Indicators

Market Signals
Indicator
PCRX
ANAB
Relative Strength Index (RSI) 82.40 39.20
Support Level $22.00 $44.25
Resistance Level $36.67 $57.55
Average True Range (ATR) 0.04 1.82
MACD -0.37 -0.05
Stochastic Oscillator 90.00 5.58

Price Performance

Historical Comparison
PCRX
ANAB

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: